<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00437983</url>
  </required_header>
  <id_info>
    <org_study_id>Memory_PS 001</org_study_id>
    <nct_id>NCT00437983</nct_id>
  </id_info>
  <brief_title>The Efficacy of Phosphatidylserine-Omega3 in Elderly With Age Associated Memory Impairment</brief_title>
  <official_title>A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Phosphatidylserine-Omega3 in Elderly With Age Associated Memory Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enzymotec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enzymotec</source>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to assess the ability of an oral administration of
      Phosphatidylserine-Omega3 to improve attention and memory complaints in comparison to placebo
      in age associated memory impaired subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Rey Auditory Verbal Learning Test</measure>
    <time_frame>baseline, 15 wk</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Work</measure>
    <time_frame>baseline,15 wk</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trail Making Test</measure>
    <time_frame>Baseline, 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Computerized Cognitive Assessment Tool</measure>
    <time_frame>baseline, 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change (CGI-C)Scale</measure>
    <time_frame>7 weeks, 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rey Osterrieth Complex Figure Test</measure>
    <time_frame>baseline, 15 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Age Associated Memory Impairment</condition>
  <arm_group>
    <arm_group_label>PS-Omega3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phosphatidylserine-Omega3, 300mg/day 15 wk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cellulose tainted with fishy odor, 3 capsules/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PS-Omega3</intervention_name>
    <description>Phosphatidylserine-Omega3 capsules 3x100mg/day 15 wk. Next, follow up phase, open label,1x100mg/day, 15 wk</description>
    <arm_group_label>PS-Omega3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo cellulose tainted with fishy odor capsules 3x100mg/day 15 wk</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to give written informed consent

          2. Age: 90≥ years ≥50

          3. Gender: male and female

          4. CDR ≤ 0.5

          5. Complaints of memory loss reflected in such everyday problems as difficulty
             remembering names of individuals following introduction, misplacing objects,
             difficulty remembering multiple items to be purchased or multiple tasks to be
             performed, difficulty remembering telephone numbers or zip codes, and difficulty
             recalling information quickly or following distraction. Onset of memory loss must be
             described as gradual, without sudden worsening in recent months. Complaints of memory
             loss to be assessed by the MAC-Q scale.

          6. Mini-Mental State Examination (MMSE) ≥27 for subjects with college education (BA) and
             ≥ 26 for all others

          7. Memory test performance that is at least 1 SD below the mean established for young
             adults on at least one neuropsychological subtest of NexAde.

          8. Language: Subjects must be able to read, write and speak Hebrew.

          9. Ability to perform tests and interviews

        Exclusion Criteria:

          1. Evidence of delirium, confusion, or other disturbances of consciousness

          2. Any Neurological disorder that could produce cognitive deterioration. Such disorders
             include AD, Parkinson's disease, stroke, intracranial hemorrhage, local brain lesions
             including tumors, and normal pressure hydrocephalus

          3. History of any infective or inflammatory brain disease including those of viral,
             fungal, or syphilitic etiologies

          4. Evidence of significant cerebral vascular pathology

          5. Head injury immediately preceding cognitive deterioration.

          6. Current psychiatric diagnosis according to DSM IV criteria of depression, mania, or
             any other major psychiatric disorder

          7. Current diagnosis or history of alcoholism or drug dependence.

          8. Evidence of depression as determined by the Geriatric Depression Scale (short version)
             score of 5 or more.

          9. Any medical disorder that could produce cognitive deterioration including renal,
             respiratory, cardiac, and hepatic disease, diabetes mellitus, endocrine, metabolic or
             hematological disturbances unless well controlled, and malignancy not in remission for
             more than two years

         10. Use of psychotropic drug or any other drug or supplement that may significantly affect
             cognitive functioning during the month prior to psychometric testing.

         11. Use of any experimental medication within 1 month prior to screening or as concomitant
             medications.

         12. Subject has a history of hypersensitivity or allergy to fish or fish oil or soy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amos Korczyn, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sourasky Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Tel Aviv Sourasky Medical Center, Neurology department</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2007</study_first_posted>
  <results_first_submitted>June 30, 2009</results_first_submitted>
  <results_first_submitted_qc>October 19, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2009</results_first_posted>
  <last_update_submitted>January 3, 2010</last_update_submitted>
  <last_update_submitted_qc>January 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Yael Richter PhD</name_title>
    <organization>Enzymotec</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through advertisements in senior citizens' homes, hospitals, and newspapers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PS-Omega3</title>
          <description>Phosphatidylserine-Omega3, 300mg/day 15 wk</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Cellulose tainted with fishy odor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PS-Omega3</title>
          <description>Phosphatidylserine-Omega3, 300mg/day 15 wk</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Cellulose tainted with fishy odor</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="78"/>
            <count group_id="B3" value="157"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.58" spread="8.12"/>
                    <measurement group_id="B2" value="72.46" spread="8.33"/>
                    <measurement group_id="B3" value="72.52" spread="8.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Rey Auditory Verbal Learning Test</title>
        <description>A widely used, brief, easy to understand scale to evaluate verbal learning and memory. The score is presented as the number of words correctly recalled (0 is worse, 15 is best).The total learning task score ranges from 0 to 45 words(0 is worse, 45 is best).</description>
        <time_frame>baseline, 15 wk</time_frame>
        <population>Analysis of per-protocol (PP) cohort. Out of the 131 participants who completed the study, nine were excluded from the PP analysis (5 from the placebo group and 4 from the PS-omega3 group), one due to short interval between visits and the rest didn’t meet the compliance criteria (≥ 65%).</population>
        <group_list>
          <group group_id="O1">
            <title>PS-Omega3</title>
            <description>Phosphatidylserine-Omega3, 300mg/day 15 wk</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cellulose tainted with fishy odor</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rey Auditory Verbal Learning Test</title>
          <description>A widely used, brief, easy to understand scale to evaluate verbal learning and memory. The score is presented as the number of words correctly recalled (0 is worse, 15 is best).The total learning task score ranges from 0 to 45 words(0 is worse, 45 is best).</description>
          <population>Analysis of per-protocol (PP) cohort. Out of the 131 participants who completed the study, nine were excluded from the PP analysis (5 from the placebo group and 4 from the PS-omega3 group), one due to short interval between visits and the rest didn’t meet the compliance criteria (≥ 65%).</population>
          <units>number of words correctly recalled</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Immediate recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.26"/>
                    <measurement group_id="O2" value="1.00" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Learning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.30" spread="0.89"/>
                    <measurement group_id="O2" value="4.02" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delayed recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="0.29"/>
                    <measurement group_id="O2" value="0.79" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Work</title>
        <time_frame>baseline,15 wk</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trail Making Test</title>
        <time_frame>Baseline, 15 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Computerized Cognitive Assessment Tool</title>
        <time_frame>baseline, 15 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Change (CGI-C)Scale</title>
        <description>The Clinical Global Impression of Change (CGI-C)scale is designed to record the clinician’s global impression of change. Global improvement score ranges from 1 = “Very much improved”, through 4 = “No change”, to 7 = “Very much worse”. Participants who experienced an improvement (scores 1, 2 or 3) in at least one of the two visits (following 7 or 15 weeks of treatment) were classified as improved over the treatment period (with the exception of participants reporting improvement following 7 weeks and deterioration at endpoint, who were NOT rated as improved)</description>
        <time_frame>7 weeks, 15 weeks</time_frame>
        <population>Analysis of per-protocol (PP) cohort. Out of the 131 participants who completed the study, nine were excluded from the PP analysis (5 from the placebo group and 4 from the PS-omega3 group), one due to short interval between visits and the rest didn't meet the compliance criteria (≥ 65%).</population>
        <group_list>
          <group group_id="O1">
            <title>PS-Omega3</title>
            <description>Phosphatidylserine-Omega3, 300mg/day 15 wk</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cellulose tainted with fishy odor</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression of Change (CGI-C)Scale</title>
          <description>The Clinical Global Impression of Change (CGI-C)scale is designed to record the clinician’s global impression of change. Global improvement score ranges from 1 = “Very much improved”, through 4 = “No change”, to 7 = “Very much worse”. Participants who experienced an improvement (scores 1, 2 or 3) in at least one of the two visits (following 7 or 15 weeks of treatment) were classified as improved over the treatment period (with the exception of participants reporting improvement following 7 weeks and deterioration at endpoint, who were NOT rated as improved)</description>
          <population>Analysis of per-protocol (PP) cohort. Out of the 131 participants who completed the study, nine were excluded from the PP analysis (5 from the placebo group and 4 from the PS-omega3 group), one due to short interval between visits and the rest didn't meet the compliance criteria (≥ 65%).</population>
          <units>Participants who experienced improvement</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rey Osterrieth Complex Figure Test</title>
        <description>A widely used neuropsychological tool for the evaluation of visuospatial constructional ability and visual memory. Both the time to complete the task (copy time)and the accuracy (immediate and delayed recall) were used as measures for the analysis. Accuracy range score is 0-36 points (0 is worse, 36 is best). Copy time is expressed in seconds (less time to copy indicates better performance).</description>
        <time_frame>baseline, 15 weeks</time_frame>
        <population>Analysis of per-protocol (PP) cohort. Out of the 131 participants who completed the study, nine were excluded from the PP analysis (5 from the placebo group and 4 from the PS-omega3 group), one due to short interval between visits and the rest didn't meet the compliance criteria (≥ 65%).</population>
        <group_list>
          <group group_id="O1">
            <title>PS-Omega3</title>
            <description>Phosphatidylserine-Omega3, 300mg/day 15 wk</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cellulose tainted with fishy odor</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rey Osterrieth Complex Figure Test</title>
          <description>A widely used neuropsychological tool for the evaluation of visuospatial constructional ability and visual memory. Both the time to complete the task (copy time)and the accuracy (immediate and delayed recall) were used as measures for the analysis. Accuracy range score is 0-36 points (0 is worse, 36 is best). Copy time is expressed in seconds (less time to copy indicates better performance).</description>
          <population>Analysis of per-protocol (PP) cohort. Out of the 131 participants who completed the study, nine were excluded from the PP analysis (5 from the placebo group and 4 from the PS-omega3 group), one due to short interval between visits and the rest didn't meet the compliance criteria (≥ 65%).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Copy Time (sec)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.27" spread="8.92"/>
                    <measurement group_id="O2" value="3.73" spread="12.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediate recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="0.68"/>
                    <measurement group_id="O2" value="1.35" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delayed recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="0.68"/>
                    <measurement group_id="O2" value="2.37" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PS-Omega3</title>
          <description>Phosphatidylserine-Omega3, 300mg/day 15 wk</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Cellulose tainted with fishy odor</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. A. Korczyn</name_or_title>
      <organization>Sourazky Tel-Aviv Medical Center</organization>
      <phone>972-3-6974229</phone>
      <email>amosk@tasmc.health.gov.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

